Initial Experience With Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination With Conventional Synthetic DMARDs in 2 US Health Care Claims Databases



      Tofacitinib is an oral Janus kinase inhibitor indicated for the treatment of rheumatoid arthritis (RA). Tofacitinib can be administered as a monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs (DMARDs). This study describes RA patients’ characteristics, treatment patterns, and costs for those initiating tofacitinib treatment as monotherapy or combination therapy, using US claims data from clinical practice.


      A retrospective cohort analysis of patients aged ≥18 years with RA (International Classification of Diseases, Ninth Revision code 714.xx) and with ≥1 tofacitinib claim in the Truven Marketscan (TM) or the Optum Clinformatics (OC) database. Index was defined as the first tofacitinib fill date (November 2012–June 2014). Patients were continuously enrolled for ≥12 months before and after index. Adherence was assessed using the proportion of days covered (PDC) and medication possession ratio (MPR). Persistence was evaluated using a 1.5× days’ supply gap or switch. All-cause and RA-related costs in the 12-month pre- and post-index periods were evaluated. Unadjusted and adjusted analyses were conducted on data on treatment patterns and costs stratified by monotherapy status.


      A total of 337 (TM) and 118 (OC) tofacitinib patients met the selection criteria; 52.2% (TM) and 50.8% (OC) received monotherapy and 83.7% (TM) and 76.3% (OC) had pre-index biologic DMARD experience. Twelve-month mean PDC values were 0.56 (TM) and 0.53 (OC), and 12-month mean MPR was 0.84 (TM) and 0.80 (OC), with persistence of 140.0 (TM) and 124.6 (OC) days. Between 12-month pre- and post-index periods, mean (SD) 12-month RA-related medical costs decreased by $5784 ($31,832) in TM and $6103 ($25,897) in OC (both, P < 0.05), whereas total costs increased by $3996 ($30,397) in TM (P < 0.05) and $1390 ($26,603) in OC. There were no significant differences in adherence, persistence, or all-cause/RA-related costs between monotherapy and combination therapy in unadjusted/adjusted analyses.


      This analysis adds to the existing tofacitinib knowledge base and will enable informed clinical and policy decision making based on valuable datasets independent of randomized controlled trials.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Smolen J.S.
        • Aletaha D.
        • Koeller M.
        • et al.
        New therapies for treatment of rheumatoid arthritis.
        Lancet. 2007; 370: 1861-1874
        • Maini R.N.
        • Breedveld F.C.
        • Kalden J.R.
        • et al.
        Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
        Arthritis Rheum. 1998; 41: 1552-1563
        • Breedveld F.C.
        • Weisman M.H.
        • Kavanaugh A.F.
        • et al.
        The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
        Arthritis Rheum. 2006; 54: 26-37
        • Keystone E.C.
        • Genovese M.C.
        • Klareskog L.
        • et al.
        Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.
        Ann Rheum Dis. 2009; 68: 789-796
        • van der Heijde D.
        • Klareskog L.
        • Rodriguez-Valverde V.
        • et al.
        Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.
        Arthritis Rheum. 2006; 54: 1063-1074
        • Zhang J.
        • Xie F.
        • Delzell E.
        • et al.
        Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients.
        Arthritis Care Res (Hoboken). 2015; 67: 624-632
        • Listing J.
        • Strangfeld A.
        • Rau R.
        • et al.
        Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register.
        Arthritis Res Ther. 2006; 8: R66
        • Heiberg M.S.
        • Koldingsnes W.
        • Mikkelsen K.
        • et al.
        The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
        Arthritis Rheum. 2008; 59: 234-240
        • Soliman M.M.
        • Ashcroft D.M.
        • Watson K.D.
        • et al.
        Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
        Ann Rheum Dis. 2011; 70: 583-589
      1. US Food and Drug Administration. Enbrel® (etanercept) solution for subcutaneous use, highlights of prescribing information, 2011. Accessed March 28, 2016.

      2. US Food and Drug Administration. Orencia® (abatacept): Highlights of prescribing information, 2011. Accessed March 28, 2016.

      3. US Food and Drug Administration. Humira® (adalimumab) injection for subcutaneous use, highlights of prescribing information, 2012. Accessed March 28, 2016.

        • Seymour H.E.
        • Worsley A.
        • Smith J.M.
        • et al.
        Anti-TNF agents for rheumatoid arthritis.
        Br J Clin Pharmacol. 2001; 51: 201-208
        • Geyer M.
        • Muller-Ladner U.
        Rationale of using different biological therapies in rheumatoid arthritis.
        Arthritis Res Ther. 2010; 12: 214
        • Curtis J.R.
        • Singh J.A.
        Use of biologics in rheumatoid arthritis: current and emerging paradigms of care.
        Clin Ther. 2011; 33: 679-707
        • Fleischmann R.
        • Kremer J.
        • Cush J.
        • et al.
        Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.
        N Engl J Med. 2012; 367: 495-507
        • van Vollenhoven R.F.
        • Fleischmann R.
        • Cohen S.
        • et al.
        Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
        N Engl J Med. 2012; 367: 508-519
        • Burmester G.R.
        • Blanco R.
        • Charles-Schoeman C.
        • et al.
        Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
        Lancet. 2013; 381: 451-460
        • Kremer J.
        • Li Z.G.
        • Hall S.
        • et al.
        Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
        Ann Intern Med. 2013; 159: 253-261
        • van der Heijde D.
        • Tanaka Y.
        • Fleischmann R.
        • et al.
        Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.
        Arthritis Rheum. 2013; 65: 559-570
        • Lee E.B.
        • Fleischmann R.
        • Hall S.
        • et al.
        Tofacitinib versus methotrexate in rheumatoid arthritis.
        N Engl J Med. 2014; 370: 2377-2386
      4. US Food and Drug Administration. Xeljanz® (tofacitinib) tablets for oral administration [prescribing information. 2012. Accessed March 28, 2016.

        • Singh J.A.
        • Saag K.G.
        • Bridges Jr, S.L.
        • et al.
        2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis.
        Arthritis Rheumatol. 2015; 68: 1-26
        • Smolen J.S.
        • Landewé R.
        • Breedveld F.C.
        • et al.
        EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.
        Ann Rheum Dis. 2014; 73: 492-509
        • Charlson M.E.
        • Pompei P.
        • Ales K.L.
        • et al.
        A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
        J Chronic Dis. 1987; 40: 373-383
        • Ting G.
        • Schneeweiss S.
        • Scranton R.
        • et al.
        Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study.
        Arthritis Res Ther. 2008; 10: R95
        • Peterson A.M.
        • Nau D.P.
        • Cramer J.A.
        • et al.
        A checklist for medication compliance and persistence studies using retrospective databases.
        Value Health. 2007; 10: 3-12
        • Curkendall S.
        • Patel V.
        • Gleeson M.
        • et al.
        Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter?.
        Arthritis Rheum. 2008; 59: 1519-1526
        • Li P.
        • Blum M.A.
        • Von Feldt J.
        • et al.
        Adherence, discontinuation, and switching of biologic therapies in Medicaid enrollees with rheumatoid arthritis.
        Value Health. 2010; 13: 805-812
      5. Nau DP. Proportion of Days Covered (PDC) as a Preferred Method of Measuring Medication Adherence, 2012. Accessed March 28, 2016.

        • Hess L.M.
        • Raebel M.A.
        • Conner D.A.
        • et al.
        Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures.
        Ann Pharmacother. 2006; 40: 1280-1288
      6. Zhao B, Wong EC, Palaniappan L. Estimating Patient Adherence to Medication with Electronic Health Records Data and Pharmacy Claims Combined. Abstract presented at: SAS Global Forum. 2013.

        • Tkacz J.
        • Ellis L.
        • Bolge S.C.
        • et al.
        Utilization and adherence patterns of subcutaneously administered anti-tumor necrosis factor treatment among rheumatoid arthritis patients.
        Clin Ther. 2014; 36: 737-747
        • Dougados M.
        • Kissel K.
        • Sheeran T.
        • et al.
        Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY).
        Ann Rheum Dis. 2013; 72: 43-50
        • Weinblatt M.E.
        • Kremer J.
        • Cush J.
        • et al.
        Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study.
        Arthritis Care Res (Hoboken). 2013; 65: 362-371
        • Bykerk V.P.
        • Östör A.J.
        • Alvaro-Gracia J.
        • et al.
        Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice.
        Clin Rheumatol. 2015; 34: 563-571
        • Gabay C.
        • Riek M.
        • Hetland M.L.
        • et al.
        Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study.
        Ann Rheum Dis. 2015; ([Epub ahead of print])
        • Burmester G.R.
        • Rigby W.F.
        • van Vollenhoven R.F.
        • et al.
        Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial.
        Ann Rheum Dis. 2015; ([Epub ahead of print])
        • Moots R.J.
        • Haraoui B.
        • Matucci-Cerinic M.
        • et al.
        Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice.
        Clin Exp Rheumatol. 2011; 29: 26-34
        • Bonafede M.M.
        • Gandra S.R.
        • Fox K.M.
        • et al.
        Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years after therapy initiation.
        J Med Econ. 2012; 15: 635-643
        • Moots R.J.
        • Mays R.
        • Stephens J.
        • et al.
        Burden of dose escalation with tumour necrosis factor inhibitors in rheumatoid arthritis: a systematic review of frequency and costs.
        Clin Exp Rheumatol. 2015; 33: 737-745
        • Stockl K.M.
        • Shin J.S.
        • Lew H.C.
        • et al.
        Outcomes of a rheumatoid arthritis disease therapy management program focusing on medication adherence.
        J Manag Care Pharm. 2010; 16: 593-604
        • Chu L.H.
        • Kawatkar A.A.
        • Gabriel S.E.
        Medication adherence and attrition to biologic treatment in rheumatoid arthritis patients.
        Clin Ther. 2015; 37: 660-666
        • Grijalva C.G.
        • Chung C.P.
        • Arbogast P.G.
        • et al.
        Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis.
        Med Care. 2007; 45: S66-S76
        • Kristensen L.E.
        • Saxne T.
        • Nilsson J.A.
        • et al.
        Impact of concurrent DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden.
        Arthritis Res Ther. 2006; 8: R174
        • Zink A.
        • Listing J.
        • Kary S.
        • et al.
        Treatment continuation in patients receiving biological agents or conventional DMARD therapy.
        Ann Rheum Dis. 2005; 64: 1274-1279
        • Du Pan S.M.
        • Dehler S.
        • Ciurea A.
        • et al.
        Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.
        Arthritis Rheum. 2009; 61: 560-568
        • Koncz T.
        • Pentek M.
        • Brodszky V.
        • et al.
        Adherence to biologic DMARD therapies in rheumatoid arthritis.
        Expert Opin Biol Ther. 2010; 10: 1367-1378
        • Desai R.J.
        • Solomon D.H.
        • Weinblatt M.E.
        • et al.
        An external validation study reporting poor correlation between the claims-based index for rheumatoid arthritis severity and the disease activity score.
        Arthritis Res Ther. 2015; 17: 83
        • Curtis J.R.
        • Chastek B.
        • Becker L.
        • et al.
        Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population.
        J Manag Care Spec Pharm. 2015; 21: 318-329
        • Curtis J.R.
        • Schabert V.F.
        • Yeaw J.
        • et al.
        Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritis.
        J Med Econ. 2014; 17: 555-566
        • Oladapo A.
        • Barner J.C.
        • Lawson K.A.
        • et al.
        Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
        J Manag Care Spec Pharm. 2014; 20: 657-667
        • Kavanaugh A.
        • Reed G.W.
        • Saunders K.C.
        • et al.
        Clinical characteristics of RA patients newly prescribed tofacitinib citrate (tofacitinib) in the United Sates after food and drug administration approval: results from the CORRONA US rheumatoid arthritis registry.
        Ann Rheum Dis. 2015; 74: 1040

      Linked Article